Memorial Sloan Kettering Cancer Center

The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia (Modern Pathology, (2021), 10.1038/s41379-021-00737-6) (2021) Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, et al. Journal article, Erratum Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? (2021) Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, et al. Journal article, Review article Molekularpathologie bei urologischen Tumoren: Empfehlungen der Konsenskonferenz der Internationalen Gesellschaft für Uropathologie (ISUP) 2019 (2021) Hommerding O, Allory Y, Argani P, Bismar TA, Bubendorf L, Canete-Portillo S, Chaux A, et al. Journal article, Review article Divergent Role for STAT5 in the Adaptive Responses of Natural Killer Cells (2020) Wiedemann GM, Grassmann S, Lau CM, Rapp M, Villarino AV, Friedrich C, Gasteiger G, et al. Journal article In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors (2020) Zeis P, Lian M, Fan X, Herman JS, Hernandez DC, Gentek R, Elias S, et al. Journal article EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? (2020) Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, et al. Journal article A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020) Mlecnik B, Bifulco C, Marliot F, Lugli A, Nagtegaal I, Hartmann A, Van Den Eynde M, et al. Conference contribution Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article